

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock code: 950)

VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF MEDICAL OFFICER

This announcement is made by the board of directors (the “**Board**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce the appointment of Mr. Sun Yuanjue (“**Mr. Sun**”) as the Chief Medical Officer of the Group with effect from 1 September 2021. Mr. Sun holds a bachelor’s degree of medicine in clinical medicine from Shanghai Medical University (now known as Shanghai Medical College, Fudan University) and a master’s degree of medicine in oncology from the Second Military Medical University (now known as Navy Medical University). He is a licensed Physician in China and has over 20 years’ experience in clinical oncology. Before joining the Group, Mr. Sun served as the Chief Physician of Medical Oncology at Shanghai Fengxian District Central Hospital since 2016, and he also served as the President of Shanghai Fengxian District Guhua Hospital during the period from July 2020 to June 2021. Prior to that, he served as Associate Chief Physician of Medical Oncology at Shanghai Sixth People's Hospital and has extensive experience in medical knowledge and clinical trial for new drugs. He had joined several academic groups as committee members, including China Anti-cancer Association (Sarcoma) and Chinese Society of Clinical Oncology (Sarcoma Specialist).

* For identification purpose only

As the Chief Medical Officer of the Group, Mr. Sun will be responsible for formulating medical strategies and product development for the Group's product introductions, formulating product development strategies, facilitating and accelerating product commercialisation process, and taking charge of medical affairs, drug registrations and compliance matters for pipeline products. To date, the Group has over 40 pipeline projects from early- to late- stage development, including 10 oncology assets in development for the treatment of a range of cancers. In addition, it is expected that the Group will obtain more new product approvals in the foreseeable future. With the joining of Mr. Sun, the Group believes that his rich experience in medical knowledge and practical experience in clinical trial and project management in the therapeutic area of oncology will inject new dynamics to the Group in various aspects, from research and development to sales and marketing, in the area of oncology and other products.

The Board would like to take this opportunity to express its warmest welcome to Mr. Sun on his new appointment with the Group.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 1 September 2021

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive directors of the Company, Dr. Li Xiaoyi is a non-executive director of the Company, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive directors of the Company.